University Clinical Hospital
Welcome,         Profile    Billing    Logout  
 0 Trials 
7 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cervantes, Andrés
Actuate 1801, NCT03678883 / 2018-003739-32: 9-ING-41 in Patients with Advanced Cancers

Active, not recruiting
2
350
Europe, Canada, US
9-ING-41, Gemcitabine - 21 day cycle, Gemzar, Doxorubicin., Doxil, Adriamycin, Lomustine, CCNU, Gleostine, Carboplatin., Paraplatin, Nab paclitaxel., Abraxane, Protein-bound paclitaxel, Nanoparticle albumin-bound paclitaxel, Paclitaxel., Taxol, Gemcitabine - 28 day cycle, Irinotecan, Camptosar
Actuate Therapeutics Inc., Actuate Therapeutics Inc
Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer, Refractory Cancer, Refractory Neoplasm, Refractory Non-Hodgkin Lymphoma, Pancreatic Adenocarcinoma, Resistant Cancer, Neoplasm Metastasis, Neoplasm of Bone, Neoplasm, Breast, Neoplasm of Lung, Neoplasms,Colorectal, Neoplasms Pancreatic, Malignant Glioma, Malignancies, Malignancies Multiple, Bone Metastases, Bone Neoplasm, Bone Cancer, Pancreas Cancer, Pancreatic Neoplasms, Breast Neoplasms, Acute T Cell Leukemia Lymphoma
01/25
01/26
NCT04259450 / 2019-003296-19: Study to Assess AFM24 in Advanced Solid Cancers

Completed
1/2
85
Europe, US, RoW
14 mg AFM24, 40 mg AFM24, 80 mg AFM24, 160 mg AFM24, 320 mg AFM24, 480 mg AFM24, 720 mg AFM24
Affimed GmbH
Advanced Solid Tumor
07/23
06/24
AFM24-102, NCT05109442 / 2021-000707-20: Study to Assess AFM24 in Combination with Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers

Recruiting
1/2
148
Europe, US, RoW
AFM24, Atezolizumab 840 MG in 14 ML Injection
Affimed GmbH, Affimed GmbH
Advanced Solid Tumor
02/25
11/25
LEGACY-2, NCT04015466: Advanced GC Multi-omic Characterization in EU and CELAC Populations

Completed
N/A
800
Europe, RoW
Fundación para la Investigación del Hospital Clínico de Valencia, Instituto Nacional de Cancerologia de Mexico, Amsterdam UMC, location VUmc, Pontificia Universidad Catolica de Chile, Vall d'Hebron Institute of Oncology, INSTITUTO ALEXANDER FLEMING, Hospital Central del IPS, IPATIMUP - Instituto De Patologia E Imunologia Molecular Da Universidade Do Porto
Gastric Cancer
12/23
12/23
LEGACY-3, NCT04019808: Gastric Cancer Risk Factors Knowledge in European and Latinamerican Population

Completed
N/A
800
Europe, RoW
Fundación para la Investigación del Hospital Clínico de Valencia, Instituto Nacional de Cancerologia de Mexico, Amsterdam UMC, location VUmc, Pontificia Universidad Catolica de Chile, Vall d'Hebron Institute of Oncology, INSTITUTO ALEXANDER FLEMING, Hospital Central del IPS, IPATIMUP - Instituto De Patologia E Imunologia Molecular Da Universidade Do Porto
Gastric Cancer
12/23
12/23
ALFAOMEGA, NCT04120935: Master Observational Trial

Recruiting
N/A
3000
Europe
Observation
IFOM ETS - The AIRC Institute of Molecular Oncology
Colorectal Cancer
07/25
12/25
NCT02636855: Screening Protocol for Tumor Antigen Expression Profiling and HLA Typing for Eligibility Determination

Recruiting
N/A
10000
Europe, Canada, US
Adaptimmune
Solid and Hematological Malignancies
11/25
11/25

Download Options